Abstract: A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.

Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.

Abstract: Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.

Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

Abstract: The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Abstract: Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.

Abstract: The disclosed subject matter relates to a textile or fabric and methods of making them that includes a composition that selectively binds odor causing and/or pathogenic bacteria, but avoids binding beneficial bacteria and an antimicrobial composition that kills the selectively bound odor causing and/or pathogenic bacteria. The composition that selectively binds odor causing and/or pathogenic bacteria can be a peptide.

Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.

Abstract: An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of ?7nAChR or TLR4 in a FLNA-captured protein complex or ?7nAChR in an A?-captured protein complex or ?7nAChR-FLNA, or TLR4-FLNA and/or ?7nAChR-A?42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.

Abstract: The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-?.

Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.

Abstract: An object of the present invention is to provide a vaccine that can simultaneously reduce A? deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-?, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.

Abstract: A method for identifying inhibitors of the primary nucleation of amyloid beta aggregation includes providing an A-beta species in solution or in a buffer, and determining the amyloid-beta aggregation, wherein the A-beta species comprises two A-beta monomer units with a linker arranged between the A-beta monomer units is provided. A method for analyzing aggregation of monomers of protein misfolding diseases and a kit are also provided.

Abstract: This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron.

Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.

Abstract: The present invention provides novel biomarkers of chronic lymphocytic leukemia (CLL). Specifically, the present invention provides methods and kits for diagnosing, assessing the level of severity, and treating of CLL.

Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.

Abstract: Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.